South Korea · Delayed Price · Currency is KRW Neuromeka Statistics
Total Valuation
Neuromeka has a market cap or net worth of KRW 828.26 billion. The enterprise value is 869.28 billion.
| Market Cap | 828.26B |
| Enterprise Value | 869.28B |
Important Dates
The last earnings date was Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neuromeka has 12.36 million shares outstanding. The number of shares has increased by 4.92% in one year.
| Current Share Class | 12.36M |
| Shares Outstanding | 12.36M |
| Shares Change (YoY) | +4.92% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 18.50% |
| Owned by Institutions (%) | 15.55% |
| Float | 10.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 43.27 |
| PB Ratio | 58.44 |
| P/TBV Ratio | 59.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -42.91 |
| EV / Sales | 45.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -38.88 |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 4.00.
| Current Ratio | 0.78 |
| Quick Ratio | 0.44 |
| Debt / Equity | 4.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.54 |
| Interest Coverage | -2.87 |
Financial Efficiency
Return on equity (ROE) is -155.17% and return on invested capital (ROIC) is -14.79%.
| Return on Equity (ROE) | -155.17% |
| Return on Assets (ROA) | -10.82% |
| Return on Invested Capital (ROIC) | -14.79% |
| Return on Capital Employed (ROCE) | -34.93% |
| Weighted Average Cost of Capital (WACC) | 20.27% |
| Revenue Per Employee | 132.00M |
| Profits Per Employee | -139.72M |
| Employee Count | 145 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 2.19 |
Taxes
In the past 12 months, Neuromeka has paid 24.84 million in taxes.
| Income Tax | 24.84M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +131.43% in the last 52 weeks. The beta is 3.07, so Neuromeka's price volatility has been higher than the market average.
| Beta (5Y) | 3.07 |
| 52-Week Price Change | +131.43% |
| 50-Day Moving Average | 73,981.00 |
| 200-Day Moving Average | 37,991.00 |
| Relative Strength Index (RSI) | 44.01 |
| Average Volume (20 Days) | 558,453 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neuromeka had revenue of KRW 19.14 billion and -20.26 billion in losses. Loss per share was -1,836.68.
| Revenue | 19.14B |
| Gross Profit | 2.61B |
| Operating Income | -15.23B |
| Pretax Income | -20.25B |
| Net Income | -20.26B |
| EBITDA | -12.52B |
| EBIT | -15.23B |
| Loss Per Share | -1,836.68 |
Balance Sheet
The company has 15.72 billion in cash and 56.72 billion in debt, with a net cash position of -41.00 billion or -3,316.50 per share.
| Cash & Cash Equivalents | 15.72B |
| Total Debt | 56.72B |
| Net Cash | -41.00B |
| Net Cash Per Share | -3,316.50 |
| Equity (Book Value) | 14.17B |
| Book Value Per Share | 1,247.46 |
| Working Capital | -10.76B |
Cash Flow
In the last 12 months, operating cash flow was -13.47 billion and capital expenditures -8.88 billion, giving a free cash flow of -22.36 billion.
| Operating Cash Flow | -13.47B |
| Capital Expenditures | -8.88B |
| Depreciation & Amortization | 2.71B |
| Net Borrowing | 16.79B |
| Free Cash Flow | -22.36B |
| FCF Per Share | -1,808.41 |
Margins
Gross margin is 13.62%, with operating and profit margins of -79.55% and -105.85%.
| Gross Margin | 13.62% |
| Operating Margin | -79.55% |
| Pretax Margin | -105.78% |
| Profit Margin | -105.85% |
| EBITDA Margin | -65.40% |
| EBIT Margin | -79.55% |
| FCF Margin | n/a |
Dividends & Yields
Neuromeka does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.92% |
| Shareholder Yield | -4.92% |
| Earnings Yield | -2.45% |
| FCF Yield | -2.70% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Neuromeka has an Altman Z-Score of 0.74 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.74 |
| Piotroski F-Score | 2 |